Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SE-1 antibody-conjugated mesenchymal stem cell exosomes
- Development stage
- Preclinical
- Lead developer
- Yonsei University Wonju College of Medicine
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SE-1 antibody-conjugated mesenchymal stem cell exosomes is an engineered exosome-based therapeutic platform being developed by researchers at Yonsei University Wonju College of Medicine for the treatment of liver fibrosis. The platform utilizes human mesenchymal stem cell (MSC)-derived exosomes that are surface-modified with polyethylene glycol (PEGylation) to extend systemic circulation and conjugated with anti-SE-1 antibodies. The SE-1 antibody specifically targets CD32b (FcγRIIb), a cell surface receptor highly expressed on differentiated liver sinusoidal endothelial cells (LSECs). By actively homing to LSECs, these engineered exosomes deliver anti-inflammatory, anti-fibrotic, and regenerative signals directly to the hepatic sinusoidal endothelium, addressing the delivery limitations of native exosomes and offering a potential precision therapy for liver fibrosis.
- Other names
- PEGylated SE-1 antibody-conjugated mesenchymal stem cell exosomesSE-1 antibody-conjugated MSC exosomesSE1 antibody-conjugated MSC exosomesSE 1 antibody-conjugated MSC exosomesSurface-engineered MSC-derived exosomes targeting SE-1 receptor on LSECsSurface-modified MSC exosomes with PEGylation and SE-1 antibody conjugation
02
Targets
FCGR2B (Fc gamma receptor IIB)
Beyond the preview
Go deeper on SE-1 antibody-conjugated mesenchymal stem cell exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SE-1 antibody-conjugated mesenchymal stem cell exosomes.